Trial Profile
A feasible study of lenalidomide for multiple myeloma in maintenance use at post autologous peripheral blood stem cell transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 22 Apr 2016 Status changed from recruiting to completed.
- 01 Nov 2013 New trial record